Abstract

Human adenovirus type B3 (HAdV-B3) causes severe respiratory infections, hence an efficient vaccine is required. Unfortunately, the presence of numerous hexon variations makes conventional vaccine designing difficult which warrants an alternative method. Therefore, an in silico multi-epitope vaccine had been constructed against appropriate hexon variants of HAdV-B3. The allergenicity, antigenicity, structure, physicochemical properties along with molecular docking with TLR-3 and TLR-9 had also been predicted. The constructed vaccine had 23 different epitopes. It showed non-allergic but antigenic nature with 30hours of half-life in vitro and exhibited thermostable nature. We anticipate that this will considerably reduce the time and expense of biological work needed for future vaccine development.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call